<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?>
<document xmlns:voc="http://www.hl7.org/v3/voc" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
<id root="08BB4884-403B-4163-BEE7-5AA40992AC4E" />
<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HUMAN PRESCRIPTION DRUG LABELING" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">ANTITUSSIVE<br /><br />HYCODAN<sup>&#174;</sup><br /></content>(Hydrocodone Bitartrate and
        Homatropine Methylbromide)<br /><content styleCode="bold">TABLETS AND
                SYRUP<br /><br />CIII<br /><br />R<sub>x</sub> only</content></title>
<effectiveTime value="20060607" />
<setId root="08BB4884-403B-4163-BEE7-5AA40992AC4E" />
<versionNumber value="1" />
<author>
  <time/>
  <assignedEntity>
   <representedOrganization>
    <name>Endo Pharmaceuticals Inc.</name>
   </representedOrganization>
  </assignedEntity>
</author>
<component>
<structuredBody>
<component>
<section>
<id root="8CDB452B-3855-8EE1-F04F-6E861E94379E" />
<effectiveTime value="20060607" />
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="63481-042" codeSystem="2.16.840.1.113883.6.69" />
<name>Hycodan</name>
<formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" />
<activeIngredient>
<quantity>
<numerator unit="mg" value="5">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="5" />
</numerator>
<denominator value="1">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="NO70W886KK" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Hydrocodone Bitartrate</name>
<activeMoiety>
<activeMoiety>
<code code="6YKS4Y3WQ7" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>hydrocodone</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="1.5">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="1.5" />
</numerator>
<denominator value="1">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="68JRS2HC1C" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Homatropine Methylbromide</name>
<activeMoiety>
<activeMoiety>
<code code="8QS6WCL55Z" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Homatropine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>Hydrocodone Bitartrate and Homatropine
                                        Methylbromide</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>calcium phosphate dibasic</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>colloidal silicon dioxide</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>lactose</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>magnesium stearate</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>starch</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>stearic acid</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator value="100">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="100" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="63481-042-70" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
<asContent>
<quantity>
<numerator value="500">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="500" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="63481-042-85" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE"><originalText>WHITE</originalText></value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"><originalText>ROUND</originalText></value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value unit="mm" value="8" xsi:type="PQ" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="2" xsi:type="INT" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255" />
<value xsi:type="ST">HYCODAN</value>
</characteristic>
</subjectOf>
<subjectOf>
<policy classCode="DEADrugSchedule">
<code code="C48676" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CIII" />
</policy>
</subjectOf>
<consumedIn>
<substanceAdministration>
<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="63481-234" codeSystem="2.16.840.1.113883.6.69" />
<name>Hycodan</name>
<formCode code="C42996" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRUP" />
<activeIngredient>
<quantity>
<numerator unit="mg" value="5">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="5" />
</numerator>
<denominator unit="mL" value="5">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="5" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="NO70W886KK" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Hydrocodone Bitartrate</name>
<activeMoiety>
<activeMoiety>
<code code="6YKS4Y3WQ7" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>hydrocodone</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="1.5">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="1.5" />
</numerator>
<denominator unit="mL" value="5">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="5" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="68JRS2HC1C" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Homatropine Methylbromide</name>
<activeMoiety>
<activeMoiety>
<code code="8QS6WCL55Z" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Homatropine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>Hydrocodone Bitartrate and Homatropine
                                        Methylbromide</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>caramel coloring</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>FD&amp;C Red 40</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>sugar</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>methylparaben</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="Z8IX2SC1OH" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>propylparaben</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>sorbitol solution</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>wild cherry imitation flavor</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator unit="[pt_us]" value="1">
<translation code="C48529" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PINT" value="1" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="63481-234-16" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<subjectOf>
<policy classCode="DEADrugSchedule">
<code code="C48676" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CIII" />
</policy>
</subjectOf>
<consumedIn>
<substanceAdministration>
<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
</section>
</component>
<component>
<section ID="A9ED2C0A-B992-4DB3-A4A9-197F96F76B0E">
<id root="B06403CE-9004-411D-F9D6-6CF18F9BBB02" />
<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DESCRIPTION" />
<title mediaType="text/x-hl7-title+xml">DESCRIPTION</title>
<text><paragraph>HYCODAN contains hydrocodone (dihydrocodeinone) bitartrate, a
                            semisynthetic centrally-acting opioid antitussive. Homatropine
                            methylbromide is included in a subtherapeutic amount to discourage
                            deliberate overdosage.</paragraph><paragraph>Each HYCODAN tablet or teaspoonful (5 mL) contains:<br />
                        Hydrocodone Bitartrate,
                            USP&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5 mg<br />
                        Homatropine Methylbromide,
                            USP&#160;&#160;&#160;&#160;&#160;1.5 mg</paragraph><paragraph>HYCODAN tablets also contain: calcium phosphate dibasic,
                            colloidal silicon dioxide, lactose, magnesium stearate, starch and
                            stearic acid.</paragraph><paragraph>HYCODAN syrup also contains: caramel coloring, FD&amp;C Red
                            40, liquid sugar, methylparaben, propylparaben, sorbitol solution and
                            wild cherry imitation flavor.
                        The hydrocodone component is
                            4,5&#945;-epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1)
                            hydrate (2:5), a fine white crystal or crystalline powder, which is
                            derived from the opium alkaloid, thebaine, has a molecular weight of
                            (494.50), and may be represented by the following structural formula:</paragraph><paragraph><renderMultiMedia referencedObject="MM00" /></paragraph><paragraph><renderMultiMedia referencedObject="MM01" /></paragraph><paragraph>Homatropine methylbromide is 8-Azoniabicyclo
                            [3.2.1]octane,3-[(hydroxyphenyl-acetyl)oxy]-8,8-dimethyl-,bromide,
                            endo-; a white crystal or fine white crystalline powder, with a
                            molecular weight of (370.29).</paragraph></text>
<effectiveTime value="20060607" />
<component>
<observationMedia ID="MM00">
<value mediaType="image/jpg" xsi:type="ED"><reference value="hycodan-figure-1.jpg" /></value>
</observationMedia>
</component>
<component>
<observationMedia ID="MM01">
<value mediaType="image/jpg" xsi:type="ED"><reference value="hycodan-figure-2.jpg" /></value>
</observationMedia>
</component>
</section>
</component>
<component>
<section ID="DCD71716-C38D-4A9A-BE7A-6DD19BE60598">
<id root="1998DB3E-FAD3-9BC3-5EE4-31776A4917AE" />
<code code="34090-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CLINICAL PHARMACOLOGY" />
<title mediaType="text/x-hl7-title+xml">CLINICAL PHARMACOLOGY</title>
<text><paragraph>Hydrocodone is a semisynthetic opioid antitussive and analgesic
                            with multiple actions qualitatively similar to those of codeine. The
                            precise mechanism of action of hydrocodone and other opiates is not
                            known; however, hydrocodone is believed to act directly on the cough
                            center. In excessive doses, hydrocodone, like other opium derivatives,
                            will depress respiration. The effects of hydrocodone in therapeutic
                            doses on the cardiovascular system are insignificant. Hydrocodone can
                            produce miosis, euphoria, physical and physiological dependence.</paragraph><paragraph>Following a 10 mg oral dose of hydrocodone administered to five
                            adult male subjects, the mean peak concentration was 23.6 &#177; 5.2                     ng/mL. Maximum serum levels were achieved at 1.3 &#177; 0.3 hours
                            and the half-life was determined to be 3.8 &#177; 0.3 hours.
                            Hydrocodone exhibits a complex pattern of metabolism including
                            O-demethylation, N-demethylation and 6-keto reduction to the
                            corresponding 6-&#945;- and
                        6-&#946;-hydroxymetabolites.</paragraph></text>
<effectiveTime value="20060607" />
</section>
</component>
<component>
<section ID="E0E356BD-3976-47B7-AB77-C67BC113A6D8">
<id root="9404A3A8-EE2E-3F63-A63C-6F82AE845C54" />
<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="INDICATIONS &amp; USAGE" />
<title mediaType="text/x-hl7-title+xml">INDICATIONS AND USAGE</title>
<text><paragraph>HYCODAN (hydrocodone bitartrate and homatropine methylbromide) is
                            indicated for the symptomatic relief of cough.</paragraph></text>
<effectiveTime value="20060607" />
</section>
</component>
<component>
<section ID="B78B335F-4CBD-4E2C-B9D6-CC6F228E85CB">
<id root="AE7AF741-8E98-94E9-6D87-8626871099E6" />
<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CONTRAINDICATIONS" />
<title mediaType="text/x-hl7-title+xml">CONTRAINDICATIONS</title>
<text><paragraph>HYCODAN should not be administered to patients who are
                            hypersensitive to hydrocodone or homatropine methylbromide.</paragraph></text>
<effectiveTime value="20060607" />
</section>
</component>
<component>
<section ID="AD2DC6B2-A88F-4470-951B-D5FBB0BF05A4">
<id root="0AFB0C4E-B716-2888-A1A8-EC819DDA70EA" />
<code code="34071-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="WARNINGS" />
<title mediaType="text/x-hl7-title+xml">WARNINGS</title>
<text><paragraph>Hydrocodone can produce drug dependence of the morphine type and,                         therefore, has the potential for being abused. Psychic dependence,
                            physical dependence and tolerance may develop upon repeated
                            administration of HYCODAN and it should be prescribed and administered
                            with the same degree of caution appropriate to the use of other opioid
                            drugs (see <content styleCode="bold"><linkHtml href="#BB7A2A66-E93F-4998-ADDB-61DCAB8AC646">DRUG ABUSE
                                    AND DEPENDENCE</linkHtml></content>).</paragraph></text>
<effectiveTime value="20060607" />
<component>
<section ID="D6CA9381-BFC1-453D-8499-54C4BA89273B">
<id root="49338136-80CC-C613-DDB4-23724384467A" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Respiratory Depression</title>
<text><paragraph>HYCODAN produces dose-related respiratory depression by
                                    directly acting on brain stem respiratory centers. If
                                    respiratory depression occurs, it may be antagonized by the use
                                    of naloxone hydrochloride and other supportive measures when
                                    indicated.</paragraph></text>
<effectiveTime value="20060607" />
</section>
</component>
<component>
<section ID="B7D9F37B-4DAC-4F99-969B-E337D145D7A4">
<id root="4A5C5C88-62F3-D217-4882-66A2218F6719" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Head Injury and Increased Intracranial Pressure</title>
<text><paragraph>The respiratory depression properties of opioids and              their capacity to elevate cerebrospinal fluid pressure may be
                                    markedly exaggerated in the presence of head injury, other
                                    intracranial lesions or a pre-existing increase in intracranial
                                    pressure. Furthermore, opioids produce adverse reactions which
                                    may obscure the clinical course of patients with head
                                injuries.</paragraph></text>
<effectiveTime value="20060607" />
</section>
</component>
<component>
<section ID="CDC17F58-1746-4BA2-8902-C79ECD73EFC6">
<id root="0FFDD583-09D9-B461-0FF0-C08B37BF7245" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Acute Abdominal Conditions</title>
<text><paragraph>The administration of HYCODAN or other opioids may
                                    obscure the diagnosis or clinical course of patients with acute
                                    abdominal conditions.</paragraph></text>
<effectiveTime value="20060607" />
</section>
</component>
<component>
<section ID="D4EE6D12-9366-4971-B745-134FD02677A9">
<id root="CC1928D3-7144-0590-A93B-8B6F62862686" />
<code code="34081-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Pediatric Use" />
<title mediaType="text/x-hl7-title+xml">Pediatric Use</title>
<text><paragraph>In young pediatric patients, as well as adults, the         respiratory center is sensitive to the depressant action of
                                    opioid cough suppressants in a dose-dependent manner. Benefit to
                                    risk ratio should be carefully considered especially in the
                                    pediatric population with respiratory embarrassment (e.g.,
                                    croup).</paragraph></text>
<effectiveTime value="20060607" />
</section>
</component>
</section>
</component>
<component>
<section ID="A21C5E39-EEE4-4EBC-B678-C67D72F1F015">
<id root="3900CC98-921C-6A1F-A88C-02F172303A99" />
<code code="42232-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PRECAUTIONS" />
<title mediaType="text/x-hl7-title+xml">PRECAUTIONS</title>
<effectiveTime value="20060607" />
<component>
<section ID="E01EE04A-3CBD-466D-B950-9169002C41F2">
<id root="F904AD30-816A-5845-62FE-6A599563F321" />
<code code="34072-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="GENERAL PRECAUTIONS" />
<title mediaType="text/x-hl7-title+xml">General</title>
<text><paragraph>Before prescribing medication to suppress or modify
                                    cough, it is important to ascertain that the underlying cause of
                                    cough is identified, that modification of cough does not
                                    increase the risk of clinical or physiological complications,
                                    and that appropriate therapy for the primary disease is
                                    provided.</paragraph></text>
<effectiveTime value="20060607" />
</section>
</component>
<component>
<section ID="D95A5B55-3405-4CED-A472-04769356126B">
<id root="37FAF45C-2B46-C0EB-A31F-F3B6CFB4DEBA" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Special Risk Patients</title>
<text><paragraph>HYCODAN (hydrocodone bitartrate and homatropine
                                    methylbromide) should be given with caution to certain patients
                                    such as the elderly or debilitated, and those with severe
                                    impairment of hepatic or renal functions, hypothyroidism,
                                    Addison's disease, prostatic hypertrophy or urethral
                                    stricture, asthma, and narrow-angle glaucoma.</paragraph></text>
<effectiveTime value="20060607" />
</section>
</component>
<component>
<section ID="B093367F-0A95-4187-9F77-F275480EACA7">
<id root="109C27BE-78F9-4DCC-B810-A7E4FB771EA8" />
<code code="34076-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Information for Patients" />
<title mediaType="text/x-hl7-title+xml">Information for Patients</title>
<text><paragraph>Hydrocodone may impair the mental and/or physical
                                    abilities required for the performance of potentially hazardous
                                    tasks such as driving a car or operating machinery. The patient
                                    using HYCODAN should be cautioned accordingly.</paragraph></text>
<effectiveTime value="20060607" />
</section>
</component>
<component>
<section ID="EB9D64F1-3B14-4C00-89AE-C4182DB0AA2F">
<id root="8C7857B9-CF31-AF11-597A-02D751CBFEB6" />
<code code="34073-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Drug Interactions" />
<title mediaType="text/x-hl7-title+xml">Drug Interactions</title>
<text><paragraph>Patients receiving opioids, antihistamines,
                                    antipsychotics, antianxiety agents or other CNS depressants
                                    (including alcohol) concomitantly with HYCODAN may exhibit an
                                    additive CNS depression. When combined therapy is contemplated,
                                    the dose of one or both agents should be reduced. The use of MAO
                                    inhibitors or tricyclic antidepressants with hydrocodone
                                    preparations may increase the effect of either the
                                    antidepressant or hydrocodone.</paragraph></text>
<effectiveTime value="20060607" />
</section>
</component>
<component>
<section ID="D39CF163-83D3-43D9-A808-46BE6EF1B6E3">
<id root="F6F32AF2-7435-FADA-4B79-B01E11DD3A94" />
<code code="34083-6" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY" />
<title mediaType="text/x-hl7-title+xml">Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
<text><paragraph>Studies of HYCODAN in animals to evaluate the
                                    carcinogenic and mutagenic potential and the effect on fertility
                                    have not been conducted.</paragraph></text>
<effectiveTime value="20060607" />
</section>
</component>
<component>
<section ID="AB1B96B2-CF53-42EA-84E4-41896E41E9F2">
<id root="95961C2C-6226-5581-A4D6-B4561D438A18" />
<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Pregnancy" />
<title mediaType="text/x-hl7-title+xml">Pregnancy</title>
<effectiveTime value="20060607" />
<component>
<section ID="C07987E7-8A2A-4E2E-B15E-2463EF91FF9A">
<id root="5B1881A4-7DB4-FF06-CD92-0A0AAC3EC357" />
<code code="34077-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="TERATOGENIC EFFECTS" />
<title mediaType="text/x-hl7-title+xml">Teratogenic Effects: Pregnancy Category C</title>
<text><paragraph>Animal reproduction studies have not been
                                            conducted with HYCODAN. It is also not known whether
                                            HYCODAN can cause fetal harm when administered to a
                                            pregnant woman or can affect reproduction capacity.
                                            HYCODAN should be given to a pregnant woman only if
                                            clearly needed.</paragraph></text>
<effectiveTime value="20060607" />
</section>
</component>
<component>
<section ID="D4A7ED03-B88B-4288-BA5D-FCDD4BA52EF6">
<id root="50261E5C-0CE0-EEC9-D742-B1ABD691C4B1" />
<code code="34078-6" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Nonteratogenic Effects" />
<title mediaType="text/x-hl7-title+xml">Nonteratogenic Effects</title>
<text><paragraph>Babies born to mothers who have been taking
                                            opioids regularly prior to delivery will be physically
                                            dependent. The withdrawal signs include irritability and
                                            excessive crying, tremors, hyperactive reflexes,
                                            increased respiratory rate, increased stools, sneezing,
                                            yawning, vomiting and fever. The intensity of the
                                            syndrome does not always correlate with the duration of
                                            maternal opioid use or dose.</paragraph></text>
<effectiveTime value="20060607" />
</section>
</component>
</section>
</component>
<component>
<section ID="CC778F49-8648-4D93-99C0-0DC5D63602B3">
<id root="AE385502-A387-8657-458F-0746AB1D8CA2" />
<code code="34079-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="LABOR &amp; DELIVERY" />
<title mediaType="text/x-hl7-title+xml">Labor and Delivery</title>
<text><paragraph>As with all opioids, administration of HYCODAN to the
                                    mother shortly before delivery may result in some degree of
                                    respiratory depression in the newborn, especially if higher
                                    doses are used.</paragraph></text>
<effectiveTime value="20060607" />
</section>
</component>
<component>
<section ID="F0843836-3FF2-46CD-86F0-2E9BA759CA38">
<id root="7C749CB9-2F8B-556C-7DD8-462E1E77AD50" />
<code code="34080-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Nursing Mothers" />
<title mediaType="text/x-hl7-title+xml">Nursing Mothers</title>
<text><paragraph>It is not known whether this drug is excreted in human
                                    milk. Because many drugs are excreted in human milk and because
                                    of the potential for serious adverse reactions in nursing
                                    infants from HYCODAN, a decision should be made whether to
                                    discontinue nursing or to discontinue the drug, taking into
                                    account the importance of the drug to the mother.</paragraph></text>
<effectiveTime value="20060607" />
</section>
</component>
<component>
<section ID="BEE58F0D-06AA-4332-BB00-01779FBCD9C7">
<id root="289CB737-5C81-121A-ABD1-74E09754A0ED" />
<code code="34081-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PEDIATRIC USE" />
<title mediaType="text/x-hl7-title+xml">Pediatric Use</title>
<text><paragraph>Safety and effectiveness of HYCODAN in pediatric patients
                                    under six have not been established.</paragraph></text>
<effectiveTime value="20060607" />
</section>
</component>
</section>
</component>
<component>
<section ID="D30B19F4-6B33-429F-9150-17E9D202C6D6">
<id root="2FC7F203-8B16-2E10-29B7-0149B44C1877" />
<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="ADVERSE REACTIONS" />
<title mediaType="text/x-hl7-title+xml">ADVERSE REACTIONS</title>
<text><paragraph><content styleCode="bold">Central Nervous System</content><br />Sedation,
                            drowsiness, mental clouding, lethargy, impairment of mental and physical
                            performance, anxiety, fear, dysphoria, dizziness, psychic dependence,
                            mood changes.</paragraph><paragraph><content styleCode="bold">Gastrointestinal System</content><br />Nausea
                            and vomiting may occur; they are more frequent in ambulatory than in
                            recumbent patients. Prolonged administration of HYCODAN may produce
                            constipation.</paragraph><paragraph><content styleCode="bold">Genitourinary System</content><br />Ureteral
                            spasm, spasm of vesicle sphincters and urinary retention have been
                            reported with opiates.</paragraph><paragraph><content styleCode="bold">Respiratory Depression </content><br />HYCODAN
                            may produce dose-related respiratory depression by acting directly on
                            brain stem respiratory centers (see <content styleCode="bold"><linkHtml href="#FAB79A45-765C-4802-8F60-A990970F53A7">OVERDOSAGE</linkHtml></content>).</paragraph><paragraph><content styleCode="bold">Dermatological</content><br />Skin rash,
                            pruritus.</paragraph></text>
<effectiveTime value="20060607" />
</section>
</component>
<component>
<section ID="BB7A2A66-E93F-4998-ADDB-61DCAB8AC646">
<id root="5AB3F615-8210-4947-9FC8-7209F303BD4F" />
<code code="42227-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DRUG ABUSE AND DEPENDENCE" />
<title mediaType="text/x-hl7-title+xml">DRUG ABUSE AND DEPENDENCE</title>
<text><paragraph>HYCODAN (hydrocodone bitartrate and homatropine methylbromide) is
                            a Schedule III opioid. Psychic dependence, physical dependence and
                            tolerance may develop upon repeated administration of opioids;
                            therefore, HYCODAN should be prescribed and administered with caution.
                            However, psychic dependence is unlikely to develop when HYCODAN is used                for a short time for the treatment of cough. Physical dependence, the
                            condition in which continued administration of the drug is required to
                            prevent the appearance of a withdrawal syndrome, assumes clinically
                            significant proportions only after several weeks of continued oral
                            opioid use, although some mild degree of physical dependence may develop
                            after a few days of opioid therapy.</paragraph></text>
<effectiveTime value="20060607" />
</section>
</component>
<component>
<section ID="FAB79A45-765C-4802-8F60-A990970F53A7">
<id root="209B5042-90F0-85E0-640E-C0B9D55A8716" />
<code code="34088-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="OVERDOSAGE" />
<title mediaType="text/x-hl7-title+xml">OVERDOSAGE</title>
<effectiveTime value="20060607" />
<component>
<section ID="D3097A99-76DE-4C69-9BB2-EF7BEF2A2D13">
<id root="807BA10A-0F88-4D6C-AC77-DF14EC34AF06" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Signs and Symptoms</title>
<text><paragraph>Serious overdosage with hydrocodone is characterized by
                                    respiratory depression (a decrease in respiratory rate and/or
                                    tidal volume, Cheyne-Stokes respiration, cyanosis), extreme
                                    somnolence progressing to stupor or coma, skeletal muscle
                                    flaccidity, cold and clammy skin, and sometimes bradycardia and
                                    hypotension. In severe overdosage, apnea, circulatory collapse,
                                    cardiac arrest and death may occur. The ingestion of very large
                                    amounts of HYCODAN may, in addition, result in acute homatropine                 intoxication.</paragraph></text>
<effectiveTime value="20060607" />
</section>
</component>
<component>
<section ID="E088CDEA-DE76-492D-83AC-742EFDFB5387">
<id root="67F0AB70-A8FE-C857-BA63-20D59862758E" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Treatment</title>
<text><paragraph>Primary attention should be given to the reestablishment
                                    of adequate respiratory exchange through provision of a patent
                                    airway and the institution of assisted or controlled
                                    ventilation. The opioid antagonist naloxone hydrochloride is a
                                    specific antidote for respiratory depression which may result
                                    from overdosage or unusual sensitivity to opioids including
                                    hydrocodone. Therefore, an appropriate dose of naloxone
                                    hydrochloride should be administered, preferably by the
                                    intravenous route, simultaneously with efforts at respiratory
                                    resuscitation. For further information, see full prescribing
                                    information for naloxone hydrochloride. An antagonist should not
                                    be administered in the absence of clinically significant
                                    respiratory depression. Oxygen, intravenous fluids, vasopressors
                                    and other supportive measures should be employed as indicated.
                                    Gastric emptying may be useful in removing unabsorbed
                                drug.</paragraph></text>
<effectiveTime value="20060607" />
</section>
</component>
</section>
</component>
<component>
<section ID="C1A29C9C-A574-45B4-962B-D7C7AE020586">
<id root="BACA08B6-5B46-66E7-35A9-71BAC9E47035" />
<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DOSAGE &amp; ADMINISTRATION" />
<title mediaType="text/x-hl7-title+xml">DOSAGE AND ADMINISTRATION</title>
<effectiveTime value="20060607" />
<component>
<section ID="C8585BCF-5F98-4D94-9E91-9C4358C1799D">
<id root="9DC80B51-D7BC-C444-6664-A93CB03BF633" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Adults</title>
<text><paragraph>One (1) tablet or one (1) teaspoonful (5 mL) of the syrup
                                    every 4 to 6 hours as needed; do not exceed six (6) tablets or
                                    six (6) teaspoonfuls in 24 hours.</paragraph></text>
<effectiveTime value="20060607" />
</section>
</component>
<component>
<section ID="CEC92CCA-F958-4EE3-850C-A26D8D7166E1">
<id root="E0000A22-8952-C9A6-8E28-886BDFE74647" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Children 6 to 12 Years of Age</title>
<text><paragraph>One-half (1/2) tablet or one-half (1/2) teaspoonful (2.5
                                    mL) of the syrup every 4 to 6 hours as needed; do not exceed
                                    three (3) tablets or three (3) teaspoonfuls in 24
                                hours.</paragraph></text>
<effectiveTime value="20060607" />
</section>
</component>
</section>
</component>
<component>
<section ID="EB0BCC3E-2405-4508-AA64-916D4E23B7AE">
<id root="7CE910E4-0378-E9DE-CBB0-FC1E4317313A" />
<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HOW SUPPLIED" />
<title mediaType="text/x-hl7-title+xml">HOW SUPPLIED</title>
<text><paragraph>HYCODAN is supplied as a white, biconvex tablet, one face
                            bisected and debossed with &#8220;HYCODAN&#8221;, and the other
                            face plain, available in:</paragraph><paragraph>Bottles of 100&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NDC
                            63481-042-70<br />Bottles of 500&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NDC
                            63481-042-85</paragraph><paragraph>Store tablets at 25&#176;C (77&#176;F); excursions
                            permitted to 15&#176;-30&#176;C (59&#176;-86&#176;F).
                            [See USP Controlled Room Temperature.]</paragraph><paragraph>Dispense in a tight, light-resistant container, as defined in the
                            USP, with a child-resistant closure (as required).</paragraph><paragraph>HYCODAN is also available as a clear red colored, wild cherry
                            flavored syrup in:</paragraph><paragraph>Bottles of one pint &#160;&#160;&#160;&#160;NDC 63481-234-16</paragraph><paragraph>Store syrup at 25&#176;C (77&#176;F); excursions
                            permitted to 15&#176;-30&#176;C (59&#176;-86&#176;F).
                            [See USP Controlled Room Temperature.]</paragraph><paragraph>Oral prescription where permitted by state law.</paragraph><paragraph>Manufactured for: <br /><content styleCode="bold">Endo
                                Pharmaceuticals Inc.</content><br />Chadds Ford, Pennsylvania 19317</paragraph><paragraph>HYCODAN<sup>&#174;</sup> is a Registered Trademark of Endo
                            Pharmaceuticals Inc.</paragraph><paragraph>Copyright &#169; Endo Pharmaceuticals Inc. 2003</paragraph><paragraph>Printed in U.S.A. <br />412042/May, 2003</paragraph></text>
<effectiveTime value="20060607" />
</section>
</component>
</structuredBody>
</component>
</document>
